Adaptimmune (ADAP) Down on End of Collaboration With Roche

Adaptimmune Therapeutics plc (ADAP) announced that its strategic collaboration with Roche’s (RHHBY) Genentech has been terminated. Shares of ADAP were down 10% on the news.Both companies collaborated in 2021 to develop and commercialize allogeneic cell therapies to treat multiple oncology indications.The collaboration had two components — the development of allogeneic T-cell therapies for up to five shared cancer targets and the development of personalized allogeneic T-cell therapies.ADAP was responsible fo ...